The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion

Area of Science:

• Oncology
• Cell Biology
• Molecular Mechanisms

Background:

• N-myc downregulated gene 1 (NDRG1) is implicated as a suppressor of prostate cancer metastasis.
• Understanding the molecular drivers of NDRG1-deficient prostate cancer cell invasiveness is crucial for developing targeted therapies.
• The precise mechanisms by which NDRG1 deficiency promotes prostate cancer cell invasion remain largely unelucidated.

Purpose of the Study:

• To investigate the molecular mechanisms underlying the increased invasiveness of NDRG1-deficient prostate cancer cells.
• To elucidate the role of NDRG1 in regulating cell adhesion, motility, and invasion pathways.
• To identify potential therapeutic targets for metastatic prostate cancer.

Main Methods:

• Analysis of integrin expression, cell adhesion, and motility in NDRG1-deficient prostate tumors.
• Assessment of Rho GTPase activity (RhoA, Rac1, Cdc42) using biochemical assays.
• Live cell imaging with fluorescent actin sensors to evaluate actin dynamics and cell migration.
• Anoikis resistance assays and 3D invasion assays.
• In vivo metastasis assays using human prostate xenografts.
• Evaluation of EMMPRIN expression and matrix metalloprotease activity.

Main Results:

• NDRG1-deficient prostate tumors exhibit reduced integrin expression, cell adhesion, and motility.
• Loss of NDRG1 leads to decreased active RhoA and Rac1, but increased active Cdc42.
• NDRG1-deficient cells show restricted actin dynamics, increased resistance to anoikis, and enhanced invasiveness.
• NDRG1 deficiency upregulates EMMPRIN expression, increasing matrix metalloproteases and invadopodial activity.
• NDRG1-deficient cells display a collective invasion phenotype and heightened invasiveness in vitro and in vivo.

Conclusions:

• Loss of NDRG1 paradoxically decreases actin-mediated cell motility while increasing prostate cancer cell invasiveness and dissemination.
• NDRG1 deficiency impacts Rho GTPase signaling and enhances EMMPRIN-mediated matrix degradation, promoting metastasis.
• These findings offer novel insights into prostate cancer progression and suggest potential therapeutic avenues targeting NDRG1-deficient metastatic cells.